ExploreWatchlistsPricing
  1. JP-listed companies
  2. Perseus Proteomics Inc.
  3. Financials
  4. Net income

Perseus Proteomics Inc. (4882)

Market cap
¥2.2B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Mar 31, 2026-718-20.65%
Mar 31, 2025-905-18.08%
Mar 31, 2024-1,104+40.34%
Mar 31, 2023-787+31.38%
Mar 31, 2022-599+44.97%
Mar 31, 2021-413-50.91%
Mar 31, 2020-842+416.23%
Mar 31, 2019-163-8.54%
Mar 31, 2018-178-5.24%
Mar 31, 2017-188-221.59%
Mar 31, 2016155

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat